Your browser doesn't support javascript.
loading
A 10-year retrospective study of lung cancer in Uganda.
Bogere, Naghib; Bongomin, Felix; Katende, Andrew; Omaido, Blair Andrew; Namukwaya, Elizabeth; Mayanja-Kizza, Harriet; Walusansa, Victoria.
Afiliação
  • Bogere N; Uganda Cancer Institute, P. O. Box 3935, Kampala, Uganda. bnaghib@gmail.com.
  • Bongomin F; Department of Medicine, Habib Medical School, Islamic University in Uganda, Kampala, Uganda. bnaghib@gmail.com.
  • Katende A; Department of Medical Microbiology & Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda.
  • Omaido BA; Ifakara Health Institute, Morogoro, Tanzania.
  • Namukwaya E; Clinical Epidemiology Unit, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Mayanja-Kizza H; Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Walusansa V; Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
BMC Cancer ; 22(1): 204, 2022 Feb 23.
Article em En | MEDLINE | ID: mdl-35197014
ABSTRACT

BACKGROUND:

Lung cancer is a leading cause of cancer-related deaths in Uganda. In this study, we aimed to describe the baseline characteristics and survival of patients with lung cancer at the Uganda Cancer Institute (UCI).

METHODS:

We retrospectively reviewed medical records of all patients with a histological diagnosis of lung cancer registered at UCI between January 2008 and August 2018. Data on demographic, clinical, and treatment characteristics, and vital status were abstracted and analyzed. Patients with undocumented vital status on the medical records were contacted through phone calls. We determined survival as time from histological diagnosis to death. The Kaplan-Meier survival analysis was performed to estimate the median survival time and the 5-year overall survival rate.

RESULTS:

Of the 207 patients enrolled, 56.5% (n = 117) were female, median age was 60 years (range 20-94), 78.7% (n = 163) were never-smokers and 18 (8.7%) were living with HIV. Presumptive anti-tuberculosis treatment was given to 23.2% (n = 48). Majority had non-small cell lung cancer (96.6%, n = 200) with 74.5% (n = 149) adenocarcinoma and 19% (n = 38) squamous cell carcinoma. All had advanced (stage III or IV) disease with 96.1% (n = 199) in stage IV. Chemotherapy (44.9%, n = 93) and biological therapy (34.8%, n = 72) were the commonest treatments used. Overall survival at 6 months, 1-, 2- and 5-years was 41.7, 29.7, 11.8, and 1.7%, respectively. The median survival time of 4.4 months was not statistically significantly different between participants with NSCLC or SCLC (4.5 versus 3.9 months, p = .335).

CONCLUSION:

In Uganda, adenocarcinoma is the predominant histologic subtype of lung cancer and patients are predominantly females, and non-smokers. Patients present late with advanced disease and poor overall survival. Public awareness should be heightened to facilitate early detection and improve outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Uganda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Uganda